Skip to main content

“I’m excited and hopeful about AT-1501 as a potential treatment for people living with ALS,” said Augie Nieto, Chairman and Co-Founder of Augie’s Quest to Cure ALS.

Novus Therapeutics announced today that the first subject has been enrolled in the Phase 2a clinical trial evaluating AT-1501, the Company’s lead product candidate, in adults with amyotrophic lateral sclerosis (ALS).  AT-1501 blocks the activation of the CD40L pathway, which has been shown to improve muscle function, slow disease progression, and improve survival in a pre-clinical animal model of ALS.

David-Alexandre C. Gros, MD, CEO of Novus Therapeutics tweeted: “There would be no AT-1501 without Augie & Lynne Nieto, Augie’s Quest, and the ALS Development Institute.  Novus Therapeutics is excited and proud to build on their extraordinary accomplishments and to continue working together to develop better treatment options for people living with ALS.”

Read the full release from Novus Therapeutics here.

ALS won’t stop and neither will Augie’s Quest

Augie’s Quest to Cure ALS
PO Box #9886
Denver, CO 80209

T: 949-506-1007

Copyright © 2022 Augie's Quest. All Rights Reserved.